Magnesium Nebulization Utilization in Management of Pediatric Asthma
Status:
Completed
Trial end date:
2019-11-22
Target enrollment:
Participant gender:
Summary
Acute asthma is the most common cause of pediatric hospitalizations. While the investigators
know that repeat inhalations of ß2 agonists and ipratropium with early oral steroids
substantially reduce hospitalizations, many children are resistant to this standard initial
therapy. About a third of children remaining in moderate to severe distress after standard
therapy are admitted to hospital and comprise 84% of pediatric acute asthma hospitalizations.
Finding safe, non-invasive, and effective strategies to treat children resistant to standard
therapy would substantially decrease hospitalizations resulting in considerable health care
savings and reduction of the psycho-social burden of the disease. While studies of magnesium
sulfate (Mg) given intravenously (IV) suggest that this agent can reduce hospitalizations in
both adults and children resistant to standard initial therapy Nebulization is an alternate
route for administering Mg. This route has the advantage of being non-invasive and is likely
much safer due to lower systemic delivery. Direct delivery via nebulization allows higher Mg
concentrations at the target site, the lower airways, with a smaller total drug dose. The
investigators propose to conduct a properly designed study to clarify the role of nebulized
Mg.
Phase:
Phase 2
Details
Lead Sponsor:
The Hospital for Sick Children
Collaborators:
Alberta Children's Hospital Canadian Institutes of Health Research (CIHR) Children's Hospital of Eastern Ontario Provincial Health Services Authority St. Justine's Hospital Stollery Children's Hospital The Children's Hospital of Winnipeg